← Home / CNS Pharmaceuticals, Inc. (CNSP)
Stock Analysis
CNS Pharmaceuticals, Inc. (CNSP)
CNSP
CNSP · Market data
5.82 +19.94%
Track CNSP in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CNSP price is:
52W Range Position
44%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 19:58 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 10.57. Holding above 5.10 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
5.10
↗
Break Above
Confirmation improves above resistance.
10.57
🎯
Next Objective
Pattern-derived target if setup continues.
7.16
×
Thesis Break
Scenario weakens below invalidation.
Below 5.10
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
4
↗
Equity Offering / Capital Raise
HIGH
CNSP equity financing update
Private Offering On May 4, 2026, CNS Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
What's Driving CNSP?
📈 Technical recovery is improving
Momentum is Neutral. Watch 10.57 for confirmation and 5.10 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 5.10
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Pattern
Inverse Head Shoulders · Confirmed
Trigger
5.53
Target
7.16
Invalidation
3.84
DT Break
fresh (age 0)
RSI(14)
61.5
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 4.89 and resistance around 11.49. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis.
Price Chart
CNSP — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$4.7M
Company size
EV
$2.2M
Debt-adjusted value
P/E
-0.3
Not meaningful
P/B
66.8
Very high
EV/EBIT
-0.1
Not meaningful
P/FCF
-0.3
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Recovering
⚖
Balance Sheet
Manageable
📈 Net Income
-4.94M
≈ Insufficient
🧮 EPS (Basic)
-7.30
≈ Insufficient
CNS Pharmaceuticals, Inc.
Related Opportunities